Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet in Primary Hyperparathyroidism
NCT03776058Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2000
- Primary completion
- Dec 2000
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in primary hyperparathyroidism (PHPT) comparing Cinacalcet with Placebo (2 arms). Primary endpoints: Number of Participants with Adverse Events at 4 weeks and Number of Participants with Clinically Significant Laboratory Tests, Vital Signs or Electrocardiogram Assessments at 4 weeks. Started Jun 2000; status: completed.
02
Drugs
cinacalcet
03
Conditions
primary hyperparathyroidism (PHPT)
Beyond the preview
Go deeper on NCT03776058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03776058.